METABOLISM

Visceral abdominal fat.

Research on the fat surrounding internal organs.

What to look for. Distinguish imaging-measured visceral fat from overall body-weight loss. Tesamorelin’s approved population has HIV-associated lipodystrophy.

FDA-approved products

Tesamorelin

Tesamorelin stimulates the body’s growth-hormone release and raises IGF-1. EGRIFTA products reduce excess abdominal fat in adults with HIV-associated lipodystrophy; clinics and community discussions also explore body composition and different weekly patterns.

Evidence in this guide: Human trials, current WR/SV labels and separately attributed clinic and community reports.

EGRIFTA WR prescribing information & Instructions for Use ↗EGRIFTA SV prescribing information & Instructions for Use ↗Pivotal phase 3 trial: visceral fat in HIV ↗

Read the Tesamorelin guide ↗

Not FDA approved

Retatrutide

Retatrutide activates GIP, GLP-1 and glucagon receptors. Researchers study body-weight, glucose and liver-fat outcomes; community discussions focus on appetite control, gradual dose changes and the lowest amount that feels effective while allowing adequate eating.

Evidence in this guide: Published trials, sponsor results and separately attributed community accounts.

Discovery: triple-receptor activity and early clinical research ↗Phase 1b: pharmacokinetics and once-weekly study dosing ↗Phase 2: obesity trial ↗

Read the Retatrutide guide ↗